TrialNature medicine2021

A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.

Allison August et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.